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Anticoagulant Mechanism of Action
of Low Molecular Weight Heparins
Theo Lindhout and H. Coenraad Hemker
Maastricht, The Netherlands
University of Limburg,
I .  INTRODUCTION
In the mid-1960s when the blood coagulation process was formulated in the
"cascade" [1] and "waterfall" [2] schemes, only the forward reactions were
considered to be of importance. The role of naturally occurring plasma inhibitors
in the regulation of thrombin generation was first studied in the years that
followed. In a series of papers by Yin and co-workers [3,4] that appeared in
1971, it was postulated that "the efficiency of activated factor X inhibitor as an
anticoagulant during normal blood coagulation (an action profoundly enhanced
by heparin) may depend more on its preventing any generated activated factor X
from activating prothrombin than it may on preventing thrombin from activating
fibrinogen." When the same investigators discovered that the activity of the
activated factor X inhibitor and that of the earlier described plasma inhibitor of
thrombin belong to the same proteinase inhibitor, they suggested that the
hemostatic balance was regulated through the neutralization of factor Xa by this
inhibitor, presently termed antithrcmbin III (AT III). Consequently, these au-
thors proposed the new name "activated factor Xa inhibitor" for AT IIL
What experimental evidence was then available to arrive at the hypothesis
that to date still forms the basis for the antifactor Xa philosophy of the antithrom-
botic action of heparin? First, it was assumed that because activated factor X is
the responsible enzyme in the prothrombin activating complex (prothrombinase),
little or no thrombin can be formed when activated factor X activity is rapidly
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neutralized. Apparently, it was believed that the coagulation of blood occurs via
a sequential series of proenzyme-enzyme conversions (the "cascade" hypoth-
esis). Support for this hypothesis was found in the results of in vivo experiments
[5,6]. It was observed that on a weight basis, factor Xa was a more potent
thrombogenic agent than thrombin in an experimental stasis thrombosis model.
Using the same arguments and assumptions, it was calculated that a complete
inhibition of thrombin generation via inhibition of factor Xa could be achieved
with a 1000-fold smaller amount of AT III than needed for direct inhibition of the
generated thrombin [7]. Since heparin dramatically enhanced the rather slow
reaction between activated factor X and AT III [8], it was thus logical to assume
that the mechanism behind the low-dose heparin therapy of the prevention of
postoperative deep vein thrombosis was the heparin-stimulated inhibition of
circulating activated factor Xa [7].
Although this hypothesis was never verified experimentally and in fact
cannot be tested directly, the very same reasoning provided the rationale behind
the development and clinical use of heparin fractions/fragments of low molecular
weight [9]. Andersson et al. [10] fractionated heparin by affinity chromatogra-
phy on matrix-bound AT III and by gel filtration. The heparin fractions thus
obtained were determinated for their so-called "specific activity" and anti-
coagulant activity. The specific activity was defined as the ability of the heparin
preparation to stimulate the AT IlVfactor Xa reaction as determined by the assay
developed by Yin et al. [11]. The anticoagulant activity was defined as the
potency of a heparin preparation to prolong the clotting time of a global test like
the activated partial thromboplastin time (APTT). The heparin fractions with low
molecular weight were found to have an anti-Xa/APTT ratio of 12, whereas
heparin fractions with high molecular weights had an anti-Xa/APTT ratio of less
than 1.
Johnson et al. [12] were the frst to demonsfate that when given subcutaneously
to humans, a low molecular weight heparin (LMWH) resulted in much higher
antifactor Xa levels than did unfractionated heparin (UFH). When the LIVIWH
preparations were further tested for their antithrombotic efficacy in an experimental
venous stasis thrombosis model developed by Wessler [13], evidence was obtained
that the antithrombotic action of heparin could be dissociated from its hemonhagic
one when the anti-Xa/APTT ratio of the heparin was 2 or more [14]. It was then
generally believed that LMWHs prevent experimental thrombosis primarily by
enhancing the inhibitory effect of the antifactor Xa activity. In addition, these first
data also suggested the occurrence of fewer hemonhagic complications. Because
these LMWHs have a diminished effect on overall clotting (less than half that of
UFH), the global anticoagulant activity of heparin was thought to cause the bleeding
problems during heparin therapy [14].
Studies on the structure-function relationship showed that in addition to a
specific pentasaccharide sequence for the interaction with AT III, additional
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activity than UFH in APTT and TCT assays'
Inpursu ing theant i -Xaconcept ,u l t ra lowmolecu la rwe igh thepar in
(ULMWH) fractions/fragments (mean molecular weight less than 3000 D) were
it"p*"d and tested in aiimal models t2l-231' However' 
no correlation between
ULMWH blood levels as measured iy antiXa 1:tlyt and impairment 
of ex-
perimentalvenousstasisthrombosiscouldbeestablished.Moreover,itisbecom.
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might relate solely to their enhancing of the reaction between thrombin and AT
III and/or the reaction between thrombin and heparin cofactor lI 124,251. Yet
heparin fractions that have antifactor Xa activity alone, such as the synthetic
pentasaccharide heparin, have an antithrombotic effect, although it is rather
weak f23,26,271. Thus it seems reasonable to assume that an effective anti-
thrombotic drug must have both antithrombin and antifactor Xa activity. Howev-
er, it must also be emphasized that the extent to which heparin is able to impair
experimental thrombosis depends largely on the type of thrombosis model and
type of stimulus used [28]. Unfractionated heparin and a ULMWH produced
comparable antithrombotic effects in a model of platelet-dependent thrombus
formation when equivalent levels of anti-Xa activity were maintained. However,
such a correlation was not found in a model of fibrin-dependent thrombosis
formation, nor in a venous stasis model [29].
Clearly, caution should attend the extrapolation of in vitro global anti-
coagulant or specific antiprotease potency figures to antithrombotic efficacy. As
a matter of fact, even the anticoagulant mechanism of action, thus the way by
which heparin (LMWH in particular) impairs thrombin generation in clotting
plasma remains uncertain. This has consequences not only for our understanding
of the relationship between anticoagulant and antithrombotic action of heparins,
but also causes confusion around the establishment of an international standard
for LMWH and the type of assays to be used to determine potency figures for
UFH and the various LMWH preparations 130-321.
At present, we have to appreciate that the antifactor Xa philosophy de-
veloped beginning in the early 1970s to explain the antithrombotic action of
low-dose heparin and later that of LMWHs cannot be maintained in view of our
current knowledge of the process of blood coagulation and of how this process is
regulated. To view the process of blood coagulation mainly in terms of sequen-
tial proenzyme-enzyme conversion reactions is certainly not correct and has to
be replaced by a staged cascade model in which the generation of multi-
component enzyme complexes are of paramount importance [33]. This chapter
therefore contains a section on the mechanism of thrombin generation as it has
emerged from biochemical studies.
Ofosu and co-workers [34] were the first to suggest that prevention of
prothrombin activating complex formation rather than the inhibition of factor Xa
might be the key step for the anticoagulant action of heparin. Uncertainties about
the role of antifactor Xa activity in the anticoagulant mechanism of action of
LMWH caused renewed interest in the other antiprotease activities of LMWHs
and most of all, antithrombin activity. In view of the mean molecular weight of
the LMWH preparations (about 4500 D), the assumed homogeneity with respect
to the maintained anti-Xa activity might no longer be relevant. Instead of that, an
even higher degree of heterogeneity than established for unfractionated heparin
could be expected. That is, the biologically active heparin species within a
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LMWH preparation are then to be found in those heparin species whose chain
length exceeds the mean molecular weight. Because these heparin species must
also contain the AT Ill-binding region, the molecular weight distribution of a
LMWH preparation alone is not sufficient to describe the heterogeneity of a
LMWH preparation. The distribution of the AT lll-binding species must also be
taken into account. Surprisingly, despite an extensive search for biological
differences among the various LMWH preparations, the latter obvious cause for
heterogeneity has not been recognized [35].
Here we wish to present studies and findings from our laboratory which
support the hypothesis that the process of blood coagulation is regulated at the
level of formation of activated blood clotting factor complexes. Heparins, in-
cluding LMWHs, impair thrombin generation by inhibition of the generation of
the essential cofactors for factor Xa and thrombin generation, either directly via
their antithrombin activitv or indirectly via their antifactor Xa activity.
I I .  MECHANISM OF THROMBIN GENERATION
A. Initiation
When blood coagulation is initiated in a natural way (tissue damage, vessel wall
lesion) or by artificial means such as kaolin (KCCT), elagic acid (APTT), or
thromboplastin (PT), the first traces of factor Xa and thrombin are generated by
enzymes lacking their cofactor (Figure 1A). At this (hypothetical) stage of the
Figure 1 Mechanism of thrombin generation: (A) initiation; (B) propagation; (C)
termination.
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B. Propagation
The free clotting enzyme factors IXa and Xa are not very efficient activators 
of
factor X and prothromlif- rerpectinely. In the presence of their 
respective
cofactors, activated factors'vlli and v, and a procoagulant surface 
(activated
bloodplatelets),their"ututyti"efficiencyincreasesfourtofiveordersofmagni-
tude [33]. To date it is nlt clear which activators of factors v and vIII 
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efficient
activator of both factors vIII and v [36], but when thrombin activity is neutral-
ized,factorXamightalsodirectlyinitiatethegenerationofbothactivatedfactors
VandVIII[37,38].Howevef,traceamountsofthrombinarealreadysufficient
to generate activated futio"'V and VIII' As a result' thrombin 
drastically
enhances its own generation (Figure 1B)'
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C. Termination
Natural inhibitors of the blood clotting serine proteases might stop or 
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destoyed and the neutralization of tissue factor by LACI (lipoprotein-associated
coagulation inhibitor) [40]. The effects ofheparin on the latter reaction system is
complex. Heparin alone (in the absence of AT III) accelerated the initial rate of
tissue factor inhibition [40]. As yet, no data are available on the differential
effects of heparin chain length and the presence of AT III binding sites on the
LACl-dependent neutralization of tissue factor.
It has been suggested that activated protein C (APC) by inactivating factor
Va might liberate factor Xa. This noncomplexed factor Xa is then rapidly
scavenged by AT Ill-heparin [41]. To what extent heparin is able to prevent he
inactivation of thrombin so as to result in a reduced amount of thrombomodulin-
thrombin complexes at the endothelial surface, causing diminished protein C
activation, is at present not known.
lll. SPECIFIC ANTIPROTEASE ACTIVITIES OF LMWHs
Unfractionated heparin, with a mean molecular weight of 12,000 to 15,000 D
has, by definition, an antifactor Xalantithrombin ratio of l. LMWHs (mean
molecular weights between 4000 and 6000 D) have ratios of 2 to 4 or more.
Ultralow molecular weight (<3000 D) heparins have only antifactor Xa activity.
The theoretical background for this is given by Lane et al. 1421, who clearly
showed by using monodisperse oligosaccharides with high affinity for AT III in
well-defined systems and under well-conEolled conditions that an octadecasac-
charide is the smallest heparin chain (Mn: 5400) that will span the saccharide
sequence required to stimulate the AT Ill-thrombin reaction. Thus they observed
an increase in antithrombin activity expressed in units per millimole of heparin
from 16 monosaccharide units and higher in both a purified and a plasma system'
The molar-specific antifactor Xa activities were fairly constant over the entire
range (8 to 18) of saccharide units tested.
A. Thrombin Inhibition
LMWH preparations are, however, certainly not comprised of well-defined
monodisperse oligosaccharides. In fact, the way in which they are prepared
causes increased heterogeneity compared with that of UFH [35]. First, the
different preparations might contain varying amounts of heparin chains that have
the ability to enhance thrombin inactivation when they also contain the AT III
binding sequence. Second, the distribution of the AT III binding species within
the population ofthe longer (>18 saccharides) chains might vary from prepara-
tion to preparation. For this reason it would be very interesting to know how for
the various LMWH preparations the functional anti-Ila heparin species are
dishibuted over the total heparin preparation. That is, the interesting question is:
How does the mean molecular weight of the entire LMWH preparation compare
with that of the anti-[a species?
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1. Exogenous a-Thrombin: Purified System
When human a-thrombin is incubated with an excess of human AT III, thrombin
activity decays according to a monoexponential model. The pseudo-first-order
rate constant of inhibition of thrombin can be calculated from the slope of a
semilogarithmic plot of residual thrombin activity versus time. When heparin is
added to this system a linear relationship is found between the amount of heparin
added and the rate constant. The kinetic constants of inhibition with the various
heparins, expressed in pseudo-first-order rate constants per microgram of heparin
per milliliter, are depicted in Figure 2A. The heparin-dependent reaction be-
tween thrombin and AT III is affected by calcium ions [43]. It is evident from
Figure 2A that Ca2+ decreases the rate constant of inhibition of thrombin equally
well for all LMWH preparations. When these values are compared with their
anti-Ila-specific activities as provided by the manufacturers, a close correlation is
found (Table 1).
2. In Situ-Generated Thrombin: Purified System
It might be argued that the kinetics of inhibition of endogenously generated
thrombin differ from that of added a-thrombin because of the presence of a
number of reaction products, such as prothrombin fragment 2 1441. We have
therefore examined the heparin-dependent neutralization reaction between AT III
and the thrombin activity formed during prothrombin activation [45-47]. Much
to our surprise we found that part of the thrombin activity generated by the
prothrombin converting complex was insensitive for the heparin-stimulated reac-
tion. We could demonstrate that with increasing prothrombin concentration the
amounts of meizothrombin (des fragment l) increased proportionally while the
amounts of a-thrombin decreased concomitantly. From another study [48] it
became clear that heparin has no affinity for meizothrombin (des fragment l),
and this could be the reason why the reaction between AT III and meizothrombin
(des fragment 1) was not stimulated by heparin.
In situ-generated thrombin was inhibited by AT Ill-heparin more slowly
than by purified thrombin. Because the presence of prothrombin activation
products was the only difference, we concluded that a noncovalent interaction
between thrombin and prothrombin fragment 1.2 or prothrombin fragment 2
caused the rather complex reaction kinetics.
3. In Situ-Generated Thrombin: Plasma System
The plasma situation is expected to be different from that of a purified system
because a number of heparin-neutralizing proteins might be present. Competition
between these proteins and AT III for heparin are thought to influence the
kinetics of the heparin-dependent thrombin inhibition. Therefore, the data
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Figure 2 Rate constants for inhibition of human a-thrombin and human factor Xa, with
and without Caz*, by heparins. (A) Human a-thrombin (10 nM) was incubated with
human AT m (500 nM) in the presence of varying amounts of heparin. (B) Human factor
Xa (10 nM) was incubated with human AT III (500 nM). (C) The ratio of the heparin-
dependent rate constants of inhibition of factor Xa over the heparin-dependent rate
constants of inhibition of thrombin.
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Table 1 Antithrombin (aIIa) Specific Activities of UFH and
LMWH
Kinetic constant
lmin t (g,g/mlftl
aIIa
Heparin type (IU/mg) Purified systema Plasma system
ISHb
ISLMWH"
CY 216
Enoxaparin
lindhout and
21.2
8 .7
2 .8
2 .8
8 .5
ndd
1 . 8
1 . 2
"Inhibition of human a-thrombin in the presence of 500 nM AT III and 4
mM Ca2+.
bFourth International Standard for Heparin.
'First International Standard for Low Molecular Weight Heparin.
qld, not determined.
obtained in a purified system (second-order rate constants) cannot be ex-
trapolated to the plasma situation. Our group has examined the heparin-
dependent inactivation of endogenous thrombin in plasma in the following way.
Defibrinated plasma was activated with thromboplastin or via contact activation.
A few minutes after the thrombin activity has reached a maximum, further
thrombin formation was blocked by adding soybean trypsin inhibitor to the
plasma. At the same time, heparin or LMWH was added and the thrombin
activity was monitored in time using a chromogenic substrate. The thrombin-like
activity was never completely neutralized, due to the formation of a thrombin/
a2-macroglobulin complex in which the thrombin partially retains its amidolytic
activity [49]. From the decay phase of the thrombin generation curve following
the addition of soybean trypsin inhibitor (STI) and heparin, a rate constant of
inhibition of thrombin was determined [50]. The normalized rate constant was
obtained from a plot of the pseudo-first-order rate constant versus heparin
concentration. The rate constants of inhibition of thrombin obtained with the
various heparin preparations are listed in Table 2. The plasma decay values are
surprisingly low compared to those obtained in a purified system. The lower
values are explained by competition between plasma proteins and AT III for
heparin (Hemker and B6guin, unpublished results). It is apparent that a greater
competitive effect is seen with UFH.
B. Factor Xa Inhibition
Heparin chains that contain the specific AT lll-binding sequence enhance the
reaction between AT ru and factor Xa, irrespective of their length. Thus
180
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Antifactor Xa Specific Activities of UFH and
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aXa
(IU/mg)
Rate constant"
lmin 1 (pcglmtr-)-tl Ratiob
ISH 180
ISLMH 168
cv 216 80
Enoxaparin 115
Pentasaccharide 800
9.8  18 .4
2.8 60.0
1 .3  6 r  .5
1.4 82.r
rr.4 70.2
ulnhibition of human factor Xa by AT III (500 nM) in the presence of
4 mM Caz+.
bRatio of the aXa specific activity (IU/mg) over the pseudo-first-
order rate constant of factor Xa inhibition per pg heparin/ml.
LMWHs retain their anti-Xa activity as long as the chain length exceeds 5 or
more saccharide units [15]. The intriguing question, however, is whether or not
the AT Ill-binding sequence is equally disnibuted over the entire range of
molecular weights. This question became urgent when it was found that the
antifactor Xa activity did vary with the chain length of an AT III high-affinity
heparin [51]. Moreover, it has also been reported that when factor Xa is
complexed with factor Va at a phopholipid surface, it is partially protected from
being inactivated by AT Ill-heparin 145,52,531. The extent of protection,
however, seemed to vary with the type of heparin used [51]' Another important
observation is that Ca2+ ions stimulate the heparin-dependent reaction between
AT III and factor Xa. Whether or not this stimulating effect was the same for
different types of heparin and human factor Xa is not clear [41].
1. Free Factor Xa: Purified System
Following the same procedure as described for thrombin, different LMWH
preparations were examined on their catalytic efficiency in the AT lll-factor Xa
inhibition reaction [47]. The experiments were performed with human proteins in
the absence and presence of Ca2+ ions. The rate constants of inhibition of factor
Xa, normalized as to weight unit, are shown in Figure 28. It is seen that Ca2+
has a twofold stimulating effect on the antifactor Xa activity of UFH. In contrast,
the antXa activity of pentasaccharide is not significantly influenced by calcium.
When these data were compared with the anti-Xa specific activities given by the
manufacturers, a marked difference became apparent between UFH and the
LMWHs. This difference is probably caused by the use of both human factor Xa
and Ca2+ ions in our assay, where bovine factor Xa and human citrated plasma
are used in the conventional anti-Xa assay (either chromogenic or clot-based).
Heparin type
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2. Factor Xa Inhibition During Prothrombin Activation
Studies of purified systems have demonstrated that the AT Ill-dependent rate of
inactivation of factor Xa is reduced when factor Xa is bound to a phospholipid
surface in the presence of factor V t5 1 I or factor Y a 145 ,521 or when bound to
activated platelets t531. It was also shown that as part of the prothrombinase
complex, factor Xa is partially protected from heparin-catalyzed inhibition
[45,51,53]. The effect of the molecular size of heparin on the rate constant of
inactivation of prothrombinase, and consequently on the extent of protection, has
been studied, but the data available are conflicting. In one study it was observed
that when factor Xa is bound to activated platelets, the protective effect di-
minishes with decreasing heparin molecular weight [53], whereas in another
study, where factor Xa was bound to a phospholipid surface in the presence of
factor V, it appeared that the protective effect became more pronounced with
decreasing molecular weight [51]. The latter observation led to the postulation
that the lack of correlation between in vitro antifactor Xa activity and anti-
thrombotic action of LMWH is caused by different inhibitory actions on free
factor Xa and on factor Xa in its more physiological form (i.e., as part of the
prothrombinase complex) [51].
In an attempt to imitate physiological conditions of factor Xa inactivation as
closely as possible, we studied the effect of AT III and heparin on factor Xa
during human prothrombin activation in the presence of an excess of factor Va
and phospholipid, so that all factor Xa was complexed with factor Va at a
phospholipid surface. The catalytic specific activities of the heparins increased
with increasing molecular size for both the inhibition of prothrombinase and
factor Xa. A lO-fold increase over the entire molecular weight range (1700 to
20,000 D) was found [47]. In contrast with the results obtained by others
[5 ] ,53] , all the heparins showed a fivefold higher rate of inhibition of facror Xa
compared with the inhibition of prothrombinase (Table 3). This indicates that the
factor Va-mediated protection of factor Xa from inhibition by AT Ill-heparin is
independent of the molecular size of the heparin. The discrepancy between our
results and that of others is explained largely by the way in which the inactivation
of factor Xa was compared with that of prothrombinase. We reasoned that the
only relevant comparison is made when the inactivation is studied under exactly
the same conditions: during prothrombin activation with factor Va as the only
variable component [47].
C. Factor lXa Inhibition
The majority of studies on the regulation of factor IXa by plasma proteinase
inhibitors have been done with purified enzyme either in plasma or buffer
[54-59]. It has been shown that bovine and human factor IXa react slowly with
AT III but do not react with a2-macroglobulin and a1-proteinase inhibitor
Mechanism of LMWHs
Table 3 Ratio of the Rate Constant of Inhibition
of Free Factor Xa to the Rate Constant of Inhibition
of Prothrombinase
Heparin M, aXalaPTase
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Pentasaccharide
Octasaccharide
10-14 Saccharide
CY 216
18-24 Saccharide
Fourth International
Standard for Heparin
HMW heparin
Source: Ref. 47.
[54,56]. It has been proposed that simultaneous binding of the inhibitor and
enzyme to the same heparin molecule is required for maximal rates of inactiva-
tion of factor IXa [55].
Indeed, we found that pentasaccharide did not stimulate the bovine factor
IXa-AT III reaction [59]. Another interesting finding of the same study was that
Ca2+ ions are absolutely required for the heparin-dependent reaction between
bovine factor IXa and AT III. tn a recent study from our group [60] on the
heparin-stimulated inhibition of factor XIa generation and factor IXa neutraliza-
tion in human plasma it was found that factor lXa-induced factor IXa activity
was not neutralized in recalcified plasma. However, when UFH was present'
factor IXa was readily inactivated: a halflife time of 8 s in the presence of I pcg
UFH/mL (or 0.15 U/mL). The same weight of pentasaccharide also caused a
shortening of the halflife time (52 s).
Both the calcium requirement and the fact that pentasaccharide also stimu-
lates the AT Ill-factor IXa reaction suggest that the reaction is different from that
between thrombin and ATIII. In the latter case, calcium reduces the heparin-
stimulating effect and the heparin chain must contain more than 18 saccharide
units to achieve a so-called "approximation effect," where binding of both the
enzyme and the inhibitor to the same heparin molecule determines the anti-Ila
activity of the heparin molecule.
D. The Anti-Xa/Anti-tla Ratio of Heparin and
Heparin Fractions
For different heparin preparations we compared the ratios of the specific catalytic
antifactor Xa activiry over the specific catalytic anti-Ila activity, as determinated
1,714
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with purified human proteins and in the presence of calcium (Figure 2C). It is
seen that ratios of the activities were the same for the Fourth International
Standard for UFH and the First International Standard for LMWH, enoxaparin,
and CY 216 16ll. Additional findings from our laboratory also suggest that the
heparin chains with anti-Xa activity in a LMWH preparation have to be found
among the longer heparin chains. consequently, the mean molecular weight as
determined for the total LMWH preparation does not necessarily represent the
mean molecular weight of the functional LMW heparin species and might
considered to be a misleading parameter [61].
IV. INHIBITION OF THROMBIN GENERATION
IN PLASMA
On the one hand, it is now generally accepted that the anticoagulant potency of a
particular heparin preparation cannot be predicted from its specific (antiprotease)
activities (i.e., inhibition of factor Xa, thrombin, and factor IXa activity). On the
other hand, no consensus has yet been obtained on the question of which of the
various possible antiprotease activities are essential for the anticoagulant mech-
anism of action of heparin and its fragments/fractions. For that reason' a logical
extension of the heparin work with purified blood coagulation proteases and
inhibitors is a study in plasma. We reasoned that any reaction that can be shown
not to play a role in plasma is very unlikely to be important in vivo. Although the
reverse is not true, studies in plasma are an interesting and necessary step in the
process of understanding the in vivo action of heparin'
A. Prothrombinase as a Target of Heparin Action in Plasma
From biochemical studies it is expected that significant thrombin generation
occurs only when factor Xa is complexed with factor Va in the so-called
"protfuombinase complex." The formation of the complex, as well as its activity,
is thought to be an important target for heparin action. Unfortunately' no assays
for plasma prothrombinase activity are available. To obtain information about
the effects of heparin and its fragments/fractions on prothrombinase' we there-
fore developed a mathematical procedure to calculate the prothrombinase activity
from experimentally derived thrombin generation curves.
1. Method of Determination
Thrombin activity as generated in plasma by thromboplastin, for example, can be
measured easily and reliably with a chromogenic substrate. Typical examples of
thrombin generation curves obtained in the absence and presence of LMWH are
shown in Figure 34. From these curves the effects of heparin on the conversion
of prothrombin into thrombin (the generation of prothrombinase activity) can be
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Figure 3 Effect of the low molecular weight heparin CY 216 on the generation of
thrombin (A) and prothrombinase activity (B) in thromboplastin-activated plasma. The
activities are expressed as a percentage of the maximum amounts in the absence of CY
216 (i.e.,320 nM thrombin and a prothrombinase activity of 700 nM throm-bin/min)' The
concentrations of CY 216 were: o, none; o' 2.5 P'gftn[-; A, 10 pglml.; L' 20 1J'gllll'I''
estimated as follows. The experimentally observed rate of thrombin formation
(the tangent to the thrombin generation curve) is at any moment the sum of two
processes (1) the rate of conversion of prothrombin into thrombin by pro-
thrombinase and (2) the rate at which thrombin activity is neutralized by anti-
proteases in plasma. The rate of inhibition of thrombin at any moment can be
calculated from the concentration of thrombin at that time and the pseudo-first-
order rate constant of inhibition of thrombin in plasma (see Section III.A.3).
There is one complicating factor-that the thrombin-like amidolytic activity in
plasma arises noi only from free thrombin but also from a complex formed
tetween thrombin and the protease inhibitor a2-macroslobulin. However, with a
variable heparin concentration, the conffibution of the latter could be eliminated.
For more details about the method, the reader is referred to a publication of
Hemker et al. [49].
2. Heparin and the Generation of Prothrombinase Activity in
T hr omb oplas tin- Ac tiv at e d P las mn
Typical examples of calculated prothrombinase activity generation curves are
rho*n in Figure 38. The generation of prothrombinase activity is followed by a
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disappearance phase. It must be emphasized that the disappearance of the
prothrombinase activity is not caused by the inhibitory action of antiproteases
(AT IID in plasma but primarily (if not solely) because of depletion of the
substrate (prothrombin). Obviously, when prothrombin is consumed during
plasma clotting, the prothrombinase activity will also disappear.
It is clearly demonstrated in Figure 38 that independent ofthe concentration
of the LMWH used, the same peak activities of prothrombinase activity were
found, indicating that under the conditions of this experiment LMWH has no
inhibitory effect on the generation of prothrombinase activity. Thus inhibition of
the net generation of thrombin must be entirely the result of the increase in the
thrombin-neutralizing potency in the presence of LMWH.
3. Classification of the Heparins According to Their
Antipr othr ombinas e and Antithr o mbin Activitie s
The method that enables us to estimate the course of prothrombinase activity in
clotting plasma clearly demonstrated that the family of heparins can be divided
into two classes: those that act like the smallest heparin fragment with antifactor
Xa activity (pentasaccharide) and those that act like standard UFH [62] ' The
pentasaccharide-like heparins (P-class) had no influence on the decay of
endogenous thrombin, but at high dosages they impaired the thrombin generation
curve by their antiprothrombinase activity. This antiprothrombinase activity
might result from an inhibition of prothrombinase formation (by inhibiting free
factor Xa) and/or by a direct inhibition of prothrombinase once it is formed.
When a limited series of LMWFI preparations and gel filtration fractions of them
were tested it was quite surprising to find that despite their increased anti-Xa/
anti-Ila ratios the LMWH preparation could be classified as S-type heparins, thus
acting on thrombin generation in plasma via their antithrombin activity. Only
those fractions that were devoid of anti-Ila activity belonged to the P-class
heparins t62-641.
4. Heparin and the Generation of Factors Xa and Va in
Thr omb oplas tin-Ac tiv ate d P lasma
From Figure 38 it is also clear that LMWH does dose-dependently prolong the
lag phase of the appearance of the prothrombinase activity and thus the onset of
thrombin generation. Since factors Xa and Va contribute equally to pro-
thrombinase activity, it remains to be established to what extent its generation is
inhibited by LMWH. To this end, generation of factors Xa and Va was moni-
tored in thromboplastin-activated plasma.
Figure 4,{ shows the effect on factor Xa generation of increasing amounts of
a LMWH preparation. As might be expected from its antifactor Xa activity (80
IU/mg), CY 216 did reduce the factor Xa yield. Interestingly, a lag phase in the
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Figure 4 Effect of low molecular weight heparin CY 216 on the generation of factor
Xa-(A) and factor Va (B) in thromboplastin-activated plasma. The activities are expressed
as indicated in Figure 3. The peak value of factor Xa was 12 rtlul and that of factor Va 25
nLI (lNVo activity). For symbols, see Figure 3.
by an inhibitor of tissue factor, called the extrinsic pathway inhibitor (EPI) or
lipoprotein-associated coagulation inhibitor (LACI)'
- -When 
rather small amounts of factor Xa (1 nM) are generated in plasma, the
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minor (if any) effect on the activation phase of the factor Xa generation curve.
They therefore exert their effects on factor Xa generation curves by neutralizing
the factor Xa activity once it is formed.
Consequently, we must conclude that the delaying effect of LMWH on the
generation of prothrombinase activity and thus on thrombin generation is certain-
ly not caused by a delayed appearance of factor Xa. The delayed appearance of
the prothrombinase activity must therefore be caused by the generation of
activated factor V. Indeed, when factor Va generation was monitored in throm-
boplastin-activated plasma, a clear lag in its appearance was noted (Figure 4B).
LMWH did prolong the lag phase. Thus it seems reasonable to assume that the
overall anticoagulant activity of heparin and LMWHs, when plasma clotting is
initiated with thromboplastin, is due to their ability to postpone factor Va
generation. This in turn raises the question: Which antiprotease activity of
heparin causes the inhibition of activated factor V generation? We tried to answer
this question indirectly by studying the effect of a synthetic pentasaccharide
heparin, having only antifactor Xa activity, on factor Va, factor Xa, and throm-
bin generation in thromboplastin-activated plasma 164,69,701. It was found that
extremely high amounts of pentasaccharide were required to obtain the same
anticoagulant effect as that obtained with UFH.
Interestingly, despite the absence of detectable amounts of factor Xa (less
than 0.1 nM in clotting plasma), factor Va generation was only slightly delayed
and so was thrombin generation. This indicates that inactivation of factor Xa
alone is a very inefficient way to prevent the plasma from completely reversing
the anticoagulant effect of heparin [69]. Nevertheless, heparins having only
antifactor Xa activity do have anticoagulant properties. The question is, howev-
er, whether the anticoagulant activity is achieved directly or indirectly. That is,
does neutralization of factor Xa result directly in less prothrombinase? Reduced
amounts of prothrombinase are also generated when factor Xa is the major
activator of factor V t711. An indirect anticoagulant effect is expected when
increased neutralization of factor Xa activity results in a reduced initial thrombin
generation, which in turn results in a diminished factor Va and thus pro-
thrombinase formation.
We have obtained strong evidence that thrombin is the only efficient enzyme
that activates factor V in clotting plasma 136,721. Our results suggest that the
anticoagulant activity of heparin and LMWH is caused primarily by their ability
to postpone the thrombin-catalyzed generation of activated factor V. Figure 5
shows plots of the clotting times as a function of the heparin concentration
expressed either as anti-Xa IU/mL or anti-Ila IU/mL. It is clearly seen that the
best correlation is found between the anticoagulant effect and the anti-Ila activity
for UFH as well as for LMWH. The poor overall anticoagulant activity of the
ULMWH pentasaccharide is clearly demonstrated.
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Figure 5 Effect of LMWHs on plasma clotting time triggered with thromboplastin' o'
Fourth International Standard for Heparin; A, First International Standard for ['ow
Molecular Weight Heparin; o, CY 216; A, pentasaccharide'
B. Tenase as Target of LMWH Action
feedback reactions: factor Xa generation and factor Va generation. Ifthe genera-
tion of the enzymatic components (factors IXa and Xa) are the rate-limiting
ip
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reactions in thrombin generation, the anti-Xa activity is expected to be of
importance. However, we already know that the intrinsic thrombin generation
(APTT) is not sensitive to the antifactor Xa activity. Alternatively, the APTT
could be sensitive for the anti-factor IXa activity of LMWH.
In a first attempt to differentiate between an effect on the generation of the
factor X activating complex and an effect on the generation of the pro-
thrombinase complex, we examined the heparin action in plasma activated with
the complete factor X activating complex (factor IXa-factor Vllla-phospholipid)
[50]. The absence of a lag phase in the generation of thrombin in these cases even
when heparin was present indicates that intrinsic prothrombinase generation
depends largely on the generation of activated factor VIII.
Pentasaccharide prolonged the lag phase of thrombin generation and reduced
the thrombin yield in contact-activated plasma. Because pentasaccharide is
devoid of thrombin activity, does not stimulate the inhibition factor IXa by AT
III at the concentrations used, and has only a weak antiprothrombinase effect, its
action can only be explained by its ability to inactivate free factor Xa when it is
formed by the intrinsic factor X activating complex. The final effect is the same
as with UFH: less free thrombin is available, although in the case of UFH the
decay of thrombin is enhanced rather than its rate of formation. In both cases
reduced rates of feedback reactions (factor VIII and factor V activation by
thrombin) will be found.
1. Heparin and the Generation of Factors VIIIa, Va, and Xa
and Thrombin in Factor Xla-Activated Plasma
Figure 6A shows that when plasma is activated with factor XIa, factor Xa
generation shows the same features as thrombin generation in thromboplastin-
activated plasma. That is, despite a linear increase in factor IXa, significant
factor Xa generation appmrs only after a certain time. Thus factor Xa generation
is not directly associated with factor IXa generation. The obvious reason is that
significant factor Xa generation occurs only when the essential cofactor offactor
IXa-activated factor VIII-is also present (Figure 6B). Whether activated
factor VIII is generated by factor Xa or thrombin cannot be concluded from the
course of factor VIIIa generation. The sudden onset of all these activated factors
occurs at about the same time. Such a phenomenon is clearly the result of linked
positive feedback reaction systems.
However, if the activation of factor VIII by factor Xa is really important,
one would expect that pentasaccharide should effectively postpone factor Xa
generation. But the opposite was found. Extremely high amounts of pentasac-
charide were required to show a comparable anticoagulant effect with UFH.
UFH (0.005 U/mL; 0.25 mg/ml,) prolonged the clotting time of factor XIa-
activated plasma from 160 s to 260 s (Figure 7A). It required a 10-fold higher
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V. EFFECT OF PIATEIETS ON THE ANTICOAGUTANT
PROPERTIES OF LMWH
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expected to be less susceptible to neutralization by platelet factor4 (PF4) because
of their lower mean mollcular weight compared with that of UFH. However, it
should not be overlooked that the anti-Ila activity is related to heparin chains
with more than 18 saccharides, and these chains do bind to PF4. Thus it is not
nonactive species.
VI. SUMMARY
Both the anti-factor Xa and anti-Ila activity of LMWH preparations could
potentially be of great importance: factor Xa is the enzyme that converts pro-
ihrombin into thrombin, and thrombin is necessary for the rapid feedback
activation of factors VIII and V, the essential cofactors for the formation of
hemostatic amounts of factor Xa and thrombin, respectively'
Our studies have indicated that:
1. The ratio of the factor Xa neutralizing potency to the thrombin neutraliz-
ing potency of the LMWH preparations tested does not differ from that of UFH
45
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when examined in purified systems using human proteins and in the presence
ua- lons.
2. Heparins with a sole antifactor Xa activity do inhibit formation of the
prothrombin converting complex at high dosages. However, when the heparins
also have (minimal) anti-Ila activity, the inhibition of formed thrombin becomes
more dominant than the reduction observed in prothrombinase activity. That is,
at already low UFH concentrations it is seen that the antiprothrombinase activity
is completely overshadowed by the direct thrombin inhibition.
3. UFH and LMWH prolong the lag phase of clotting in plasma, activated
through either the extrinsic or intrinsic pathway, by inhibition oi the formation of
the factor X and prothornbin activating complexes. The ultimate targets of
LMWH action are the thrombin-dependent feedback reactions (e.g., activation
of factors V and VIII).
4. UFH and LMWH inhibit coagulation in platelet-rich plasma activated
with low amounts of thromboplastin by eliminating trace amounts of thrombin
necessary for triggering the platelet procoagulant reactions.
5. The relatively high amounts of nonanticoagulant species in LMWH
preparations might protect the species with anti-Ila activity for neutralization bv
platelet factor 4.
6. The ideal test for both LMWHs and UFH would be one that shows the
effect of heparin on the amount of free thrombin generated during the course of a
thrombin generation test and thus independent of the way in which this amount
has been diminished.
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